Refine by
Critical Care Articles & Analysis
127 news found
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...
The research demonstrates a clinical sensitivity at a landmark of 61.1% and a robust surveillance performance with longitudinal sensitivity of 83.3% and specificity of 89.5% across stage II/III CRC patients. xM MRD results predict disease-free survival (DFS) nearly 5 times stronger compared to standard of care carcinoembryonic antigen (CEA) level (Adj. Hazard Ratio of 9.69 vs. ...
ByTempus
“We are thrilled to welcome Tom and Marc to the Tris Pharma executive team, and I am confident that their expertise will play a critical role in helping us continue to develop and commercialize differentiated approaches that enhance therapeutic benefit and optimize outcomes for patients,” said Ketan Mehta, founder and chief executive officer of Tris Pharma. ...
Two of the hospitals are part of leading healthcare organizations in New Jersey – one that comprises 17 hospitals, and the other that offers more than 400 sites of care, including hospitals, physician practices, urgent care centers, outpatient centers, physical rehabilitation, and home care, along with multiple specialty centers and ...
Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of BVA-guided care on decongestion therapy and outcomes versus standard of care. In both study arms, patients had BVA testing within a day of admission and one day prior to discharge, along with physician assessment for congestion. ...
Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure ...
The leading use of nanoRBC is in correcting insufficient blood flow and oxygen supply in critical care patients and those in need of blood transfusions. In this, nanoRBC is a major breakthrough (after a half-century of failed efforts by many companies) in the development of a safe alternative to RBC transfusion. nanoRBC, also holds great promise for use as a ...
Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure ...
“Participation of industry partners like Daxor allows HFSA to provide valuable benefits to our members and helps us improve and expand heart failure care through education, research, and advocacy.” Kathy Kornafel, Daxor’s VP of Marketing and Commercial Development added, “Our corporate membership provides us access to HFSA leadership and year-round ...
Commercial and Pipeline Update Product portfolio Acute Care Hospital: RYANODEX®, vasopressin, Barhemsys®, Byfavo® Oncology: BENDEKA, BELRAPZO, PEMFEXY11, TREAKISYM Japan12 75-person commercial team covers all products excluding BENDEKA and TREAKISYM Company projects growth in earnings while still supporting R&D Cash flow from legacy products expected ...
” “More than 135 published peer-reviewed studies, and over a dozen this past year alone, have proven that blood volume analysis informs clinicians with critical information to manage and treat volume derangements in heart failure and many other medical conditions,” said Michael Feldschuh, President, and CEO of Daxor Corporation. ...
Since its initial launch in February 2022, PEMFEXY has been an important addition to Eagle’s hospital and acute care product portfolio, and we are pleased to bring this treatment option to patients undergoing chemotherapy. ...
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. ...
Having a treatment that can help patients breathe easier and live a better quality of life, without surgical intervention, will be a major step forward in COPD care in Japan.” Over 600,000 Japanese patients suffer from severe COPD, including approximately 100,000 patients with severe disease where hyperinflation causes them to remain symptomatic despite adhering to their ...
Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure ...
Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure ...
Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure ...
“Daxor has been a tremendous partner with MedAxiom as we work to transform cardiovascular care and improve heart health. Daxor’s BVA technology provides accurate and actionable data, leading to improved patient outcomes and meaningful cost savings. ...
Our test informs clinicians with critical information to help manage and treat volume derangements in complex HF patients and past studies in peer-reviewed journals have shown substantial improvements in reducing mortality, hospital readmission, length of stay, and costs from the use of our ...
We look forward to sharing with the experts how our diagnostic provides them with accurate, actionable data to individualize treatment plans in both the inpatient and outpatient settings – improving outcomes and reducing the total cost of care,” said Michael Feldschuh, CEO and President of Daxor Corporation. ...